anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides viral vectors that have been engineered to contain a synthetic promoter that controls at least one essential gene. The synthetic promoter is induced by a specific gene product not normally produced in the cells in which the viral vector is to be transferred. The vectors are propagated in producer or helper cells that express the inducing factor, thereby permitting the virus to replicate to high titer. The lack of the inducing factor in the target cells precludes viral replication, however, meaning that no vector toxicity or immunogenicity arises. Where the virus carries a gene of interest, this should provide for higher level expression for longer periods of time than with current vectors. Methods for making the vectors, helper cells, and their use in protein production, vaccines and gene therapy are disclosed.
The GPPAD-POInT-Study aims to determine whether daily administration of oral insulin to children from age 4 months - 7 months with elevated genetic risk for type 1 diabetes reduces the cumulative incidence of beta-cell autoantibodies and diabetes in childhood. The purpose of the GPPAD-POInT-Study is to induce immune tolerance to beta-cell autoantigens through regular exposure to oral insulin for a period of 29 to 32 months. Together with the results of the Pre-POINT-Early Study, this phase IIb study aims to investigate and consolidate the findings from the pilot Pre-POINT Study, namely safety and immune efficacy at a daily dose of 67.5 mg oral insulin. Since babies and young children will be tested in the GPPAD-POInT-Study, the 67.5 mg dose will be reached by dose escalation starting at 7.5 mg for 2 months, followed by exposure to 22.5 mg for 2 months, and reaching the desired 67.5 mg dose. The GPPAD-POInT-Study aims to recruit 1040 children into the trial.

The active substance for oral application is human insulin. Oral Insulin will be applied as a capsule containing 7.5, 22.5 and 67.5 mg of the active substance together with filling substance microcrystalline cellulose.
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary medicine, namely to methods for preparing preparations for the diagnosis of pregnancy and infertility of cows and heifers. For the preparation of a rabbit with a mass of 1.5–2 kg, 4-fold with an interval of 7 days, subcutaneously in the scapula area, is immunized with the antigen "Human chorionic gonadotropin", in a dose of 2,000 U, diluted in 1 ml of Freud's sterile adjuvant. 10 days after the last injection of the hormone, the serum is obtained by sedimentation, then 2 ml of the obtained immune serum diluted 1:5 in 1 % boric acid solution is added to 10 ml of a suspension of fine particles of 1–1.6 mcm alizarin. Mixture is kept at 37 °C for 2 hours and another 13 hours at a temperature of 4–8 °C, then the mixture is centrifuged to clarification, add to the precipitate 10 ml of a 2 % solution of normal rabbit serum in 0.5 % boric acid in saline solution and preserve with quinosol (merthiolate) in a ratio of 0.01 g of preserving agent per 100 ml of the liquid obtained after dissolving the precipitate. 6 % sucrose is added to the resulting mixture as the forming agent, cryoprotectant and stabilizer, then the resulting mixture is poured into sterile test tubes in a volume of 2 ml, placed in a freezer at a temperature of +20 °C. Temperature is then reduced to -20 °C and maintained for 1 hour, after that, the temperature is reduced from -20 °C to -30 °C with an exposure time of 1 hour, then the temperature is reduced from -30 °C to -40 °C with an exposure time of 1 hour, then the chamber is cooled to a temperature of -45…-50 °C, the holding time at this temperature is 3 hours, then for 3 hours the samples are kept in a freeze chamber at a temperature of -50 °C with the lowest pressure of 5.0×10 mbar. After that, at a speed of 4 °C/h, the temperature is increased from -50 °C to -10 °C, further the temperature in the chamber is increased from -10 °C to +4 °C at speed of 2 °C/hour, and +4 °C to +20 °C at a speed of 5 °C/hour, then the preparation is dried for 3 hours at a temperature of +20 °C, then the test tubes are closed with sterile caps.EFFECT: use of this method makes it possible to obtain a lyophilized preparation for the diagnosis of pregnancy.1 cl
PURPOSE:To provide safe orthodontic parts made of titanium having excellent mechanical characteristics. CONSTITUTION:The orthodontic parts made of the titanium are produced by a stage for obtaining a mixture by mixing titanium raw material powder and a binder, a stage for obtaining moldings by injection molding the mixture, a stage for removing the binder in the moldings and a stage for obtaining sintered compacts by sintering the moldings from which the binder is removed. The sintered compacts obtd. in such a manner have a compsn. contg. <=0.25wt.% carbon and <=0.6wt.% oxygen and the balance Ti with inevitable impurities and the relative density thereof is >=97.0%.
The objective of this study was to ascertain the relationship between the weight-adjusted waist index (WWI) and the risk of stroke in an elderly hypertensive population, a relationship that has not been previously elucidated. The Cox regression model was employed to assess the correlation between baseline WWI measurements and the incidence of stroke. To further elucidate the shape of the association between baseline WWI and stroke, restricted cubic splines were employed. Furthermore, subgroup analyses and interaction tests were carried out to investigate potential heterogeneities. Our study cohort comprised 4962 hypertensive individuals aged 60 years or older with no prior history of stroke. Over a median follow-up of 3.2 years, we found 547 new-onset stroke cases. After adjusting for confounding variables, the Cox regression analysis revealed a positive association between baseline WWI and the risk of stroke, with hazard ratios (HRs) escalating progressively as WWI values increased. When compared to the lowest quartile of WWI, the highest quartile demonstrated an HR of 1.87 (95% CI, 1.44-2.42) for stroke. Subgroup analyses confirmed the consistency of this relationship across different demographic and clinical strata. The study findings indicate that an elevated WWI is significantly related with a higher risk of new-onset stroke among elderly patients with hypertension. These results underscore the importance of WWI as a potential risk stratification tool. To confirm these results and explore the causal mechanisms behind the observed correlation, more study is necessary.
FIELD: medicine, oncology. SUBSTANCE: invention relates to vaccine used for stimulation of antitumor immunity. Invention involves vaccine composed of xenogenic tumor cells (murine carcinoma and melanoma cells) and xenogenic nontumor cells (porcine testicle cells) that are able to stimulate human antitumor immune responses efficiently. After penetration in body xenogenic cells are subjected for acute rejection mediated by natural antibodies and this process is accompanying with active implication of professional antigen-presenting (dendritic and macrophagial) cells in antitumor immune processes. EFFECT: enhanced antitumor immunity, valuable medicinal properties. 2 cl, 1 dwg, 1 tbl
BACKGROUND: Stoma creation is standard in general surgery, yet complication rates remain high.
PURPOSE: This study investigated the incidence and risk factors for early postoperative stoma complications in elective vs emergency surgery.
METHODS: All patients who underwent stoma creation between June 2015 and November 2020 were retrospectively reviewed and analyzed. Patients were divided into 2 groups based on the surgery type: elective vs emergency.
RESULTS: A total of 375 patients were included in this study. Two hundred fifty-three patients (67.5%) underwent elective stoma creation, while 122 (32.5%) underwent stoma creation during an emergency surgery. In the emergency group, white blood cell, blood urea nitrogen, and creatinine levels were statistically significantly higher (P = .001, .001, and .002, respectively). Albumin levels were statistically significantly lower in the emergency group (P = .001). The mean Emergency Surgery Score was 5.17 ± 2.73 in the emergency group compared to 4.4 ± 2.44 in the elective group (P = .006). Colorectal cancer was the most common cause of stoma creation in both groups. In terms of stoma creation, colostomy was statistically significantly more common in the emergency group (59%, P = .001), compared to ileostomy in the elective group (58.9%, P = .001). Complications were observed in 135 of all patients (36%). Necrosis was statistically significantly more common in emergency cases (9.9%, P < .001).
CONCLUSION: Surgeons should strive to optimize the patient's condition prior to the operation and, if possible, perform stoma marking or involve a stoma nurse in the operating room to select the most suitable site. In high-risk patients, where complications are more likely, the use of a stoma should be minimized and definitive management should always be pursued if feasible.
AuraGain insertion:AuraGain LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
The invention relates to a Tigliane diterpenoid compound stellchamain A. The invention also provides a preparation method of the compound and application of the compound in preparation of a medicament for treating psoriasis. The invention adopts a separation technology to extract the Chinese medicine stellera chamaejasme to obtain the monomer compound SA. Through deep research on pharmacological actions of SA and relation between the SA and an immune microenvironment, the SA is found to improve the immune microenvironment by reducing the STAT1-S100A9 axis induced by IL-17, so that the effect of treating psoriasis is achieved. These results provide a powerful scientific basis for SA as a potential psoriasis therapeutic drug, and also provide a new idea for further developing novel therapeutic strategies with immunoregulatory effects. However, further research and clinical trials are needed to verify their safety and efficacy, providing a more solid basis for their clinical use.
The Practitioner enters a gassho (two hands coming together at the heart) meditative state with the Distance Symbol. Reiji-ho - moving the joined hands until the thumbs touch the space between the brows. Going into a relaxed state by using a breathing technique. Say the person's name three times. Proceed with byosen (method using the sensitivity in the hands to treat those areas in need of Reiki) scanning technique. Chiryo (standard session visualizing all hand positions) for 5 minutes each: Jawbone-Back of the head-Throat-Lungs-Area of participant's concern-Stomach-Intestines-Kidneys-Spinal cord. At the end of the session, visualize towards the participant's feet to help integrate the healing. Visualize brushing the Biomagnetic field around the participant's body from head to feet. Inform the participant that the session has been completed. Include time to rest quietly for a few minutes. Encourage participant to sip water (if they prefer) and ask them about their experience.
Methods for treating cancer are disclosed which comprise administering to a subject T cells which have been pretreated ex vivo or in vitro with fenofibric acid (FFA), an FFA prodrug, or a derivative thereof that has PPAR-α agonist activity. These compounds promote the use of fatty acid catabolism rather than glucose for energy and promote enhanced recovery of, and biomass production by, the pre-treated T cells. Still other methods comprise co-administering to a subject having a cancer characterized by a solid tumor an immunotherapeutic composition targeting an antigen or ligand on the tumor cell and the pretreated T cells. The method may also employ co-administration of a checkpoint inhibitor. Novel compositions comprise the pre-treated T cells. Novel FFA prodrugs are provided.
Clinical studies of Pentobarbital Sodium have not included sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Elderly patients may react to barbiturates with marked excitement, depression, and confusion. In some persons, barbiturates repeatedly produce excitement rather than depression. Dosage should be reduced in the elderly because these patients may be more sensitive to barbiturates.
Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban)for 2 months. We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity after exposure to videotapes showing smoking and neutral scenes in Positron Emission Tomography using FDG. There were 2 scanning sessions, one with a smoking videotape and one with a neutral video separated by a week. So far we have compared the brain's metabolic activity in 6 abstinent smokers and 6 still smokers.
Neutral complexes of polyvinylpyrrolidone (PVP) and iodine which are insoluble in water and organic solvents, are new. They are slow-release antibacterial agents for use in human and veterinary medicine, as plant protection agents and in disinfection, e.g. of drinking water, swimming pools, etc. The compsns. do not give rise to a very acid reaction by reaction of iodine in aq. media and the complexes do not lose a third of the iodine as do known compsns. The complexes are prepd. by heating PVP with elementary iodine (0.5-18%) for 4-10 hr. at 50-120 degrees C after prepliminary stirring at room temp.
COX-2 plays a key role in converting arachidonic acid into prostaglandins. This makes it a significant target for treating inflammation. Selective COX-2 inhibitors have marked a new phase in inflammatory treatment, providing significant effectiveness while reducing negative side effects. Herein, we aimed at the design and synthesis of new anti-inflammatory agents 5a-f, 7a-b, 10a-f, and 13a-b with expected selective inhibition for COX-2. Compounds 5d-f, 7b, and 10c-f showed significant COX-2 inhibition with IC50 in the range of 0.06-0.09 μM, indicating powerful pharmacological potential. In light of this, eight compounds were selected for further testing in vivo to assess their selectivity toward COX-1/COX-2 enzymes with the ability to reduce paw thickness. Compounds 5f and 7b showed significant anti-inflammatory effects without causing stomach ulcers, as they showed significant in vivo inhibition for paw thickness at 63.35% and 46.51%, as well as paw weight at 68.26% and 64.84%. Additionally, the tested compounds lowered TNF-α by 61.04% and 64.88%, as well as PGE-2 by 60.58% and 57.07%, respectively. Furthermore, these potent compounds were thoroughly analyzed for their pain-relieving effects, histological changes, and toxicological properties. Assessing renal and stomach function, as well as measuring liver enzymes AST and ALT, together with kidney indicators creatinine and urea, offered valuable information on their safety profiles. Molecular modeling studies explain the complex ways in which the strong interacts with the COX-2 enzyme. This comprehensive strategy emphasizes the therapeutic potential and safety profiling of these new analogues for managing inflammation.
Seizure occurred in 0.6% of patients receiving XTANDI in eight randomized clinical trials. In these trials, patients with predisposing factors for seizure were generally excluded. Seizure occurred from 13 to 2250 days after initiation of XTANDI. Patients experiencing seizure were permanently discontinued from therapy, and all seizure events resolved.

In a single-arm trial designed to assess the risk of seizure in patients with pre-disposing factors for seizure, 8 of 366 (2.2%) XTANDI-treated patients experienced a seizure. Three of the 8 patients experienced a second seizure during continued treatment with XTANDI after their first seizure resolved. It is unknown whether anti-epileptic medications will prevent seizures with XTANDI. Patients in the study had one or more of the following pre-disposing factors: the use of medications that may lower the seizure threshold (~ 54%), history of traumatic brain or head injury (~ 28%), history of cerebrovascular accident or transient ischemic attack (~ 24%), and Alzheimer’s disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months, past history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection (all < 5%). Approximately 17% of patients had more than one risk factor.

Advise patients of the risk of developing a seizure while receiving XTANDI and of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others.

Permanently discontinue XTANDI in patients who develop a seizure during treatment.
BACKGROUND: This study aimed to explore the prevalence and related risk factors of sarcopenia in patients on maintenance hemodialysis (MHD).
METHODS: This cohort study enrolled 165 patients on MHD. The patients were divided into sarcopenia and non-sarcopenia groups based on the presence of sarcopenia or not. Sarcopenia was diagnosed according to the consensus of the Asian Sarcopenia Working Group that considers reduced muscle mass and decreased muscle strength (19). The muscle mass was measured using the multi-frequency bioelectrical impedance (Inbody260) and skeletal muscle index (SMI) was used: <7.0 kg/m2 (male); <5.7 kg/m2 (female) - with muscle mass reduction. The electronic grip dynamometer was used for measuring dominant handgrip strength (HGS) to reflect muscle strength. Male patients with HGS < 28 kg and female patients with HGS < 18 kg were considered with a decrease in muscle strength. The demographic characteristics, laboratory indexes, anthropometrical measurements, body compositions, and InBody score were compared between groups. The multivariate logistic regression was used to explore the risk factors for sarcopenia.
RESULTS: Of the 165 patients on MHD, 36 had sarcopenia, and the prevalence was 21.82%. Patients in the sarcopenia group had higher ages and lower body mass index, serum albumin level, circumference of waist, hip, and biceps, handgrip strength, total water content, protein inorganic salt concentrations, skeletal muscle mass, basal metabolic rate, obesity degree, SMI, and body fat content. The multivariate logistic regression showed that age, waist circumference, handgrip strength, and InBody score were influencing factors for sarcopenia in patients on hemodialysis.
CONCLUSION: The prevalence of sarcopenia was high in patients on MHD. Higher age, lower waist circumference, lower handgrip strength, and lower InBody score were independent risk factors for sarcopenia in such patients.
Neutrophil extracellular traps (NETs) are intricate fibrous structures released by neutrophils in response to specific stimuli. These structures are composed of depolymerized chromatin adorned with histones, granule proteins, and cytosolic proteins. NETs are formed via two distinct pathways known as suicidal NETosis, which involves NADPH oxidase (NOX), and vital NETosis, which is independent of NOX. Certain proteins found within NETs exhibit strong cytotoxic effects against both pathogens and nearby host cells. While NETs play a defensive role against pathogens, they can also contribute to tissue damage and worsen inflammation. Despite extensive research on the pathophysiological role of NETs, less attention has been paid to their components, which form a unique structure containing various proteins that have significant implications in a wide range of diseases. This review aims to elucidate the components of NETs and provide an overview of their impact on host defense against invasive pathogens, autoimmune diseases, and cancer.
Participants access the Educational Website and Facebook page about rheumatoid arthritis for a period of one week. After 1 week, research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
The lotion comprises >=1 plant alcohol in which is macerated >=1 variety of flowers of the labiatae family. The lotion is prepd. by macerating the fresh flowers in the plant alcohol, partic. a fruit alcohol, and then filtering the liquor. The alcohol is pref. of strength X40 degrees-X70 degrees. Specified are a brandy or an alcohol from plums or grapes. Specified as a flower is rosemary.
Disclosed is a method for producing sodium ion-free X carbonate or hydrocarbonate effervescent powder, granulate or tablets. In said method, the active substances X, where X represents at least calcium carbonate, are humidified with a small amount of alcohol and water and are mixed as a powder with a small amount of lactobionic acid in a partial vacuum obtained by continuous pumping in a vacuum tank. This causes the calcium salt (CaCO3) of the calcium in the surface layer of the powder particles to react with the lactobionic acid, effervesce and release some CO2 . As a result, the pressure in the vacuum tank rises, and once the effervescence reaction has been completed, the internal pressure in the vacuum tank drops to the initial value under the effect of the continuous pumping action, and the powder dries. Upon removal of the dry powder from the vacuum tank, an acid, preferably citric acid, is added as an effervescent agent, and the powder is then optionally pressed to obtain tablets. The obtained sodium ion-free calcium carbonate effervescent tablet thus contains at least calcium carbonate and citric acid as an effervescent agent, the surface layer of the pressed particles having been subjected to preliminary effervescing using lactobionic acid.
Patients receive ipilimumab IV over 90 minutes on day 1 and sargramostim (GM-CSF) SC on days 1-14. Treatment repeats every 28 days for 4-6 courses. GM-CSF continues beyond 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Some patients undergo blood sample collection periodically for laboratory and pharmacokinetic studies. Samples are analyzed for human anti-human antibodies, IgG antibodies to ipilimumab semi-quantitative ELISA assay, and plasma concentrations of ipilimumab via quantitative ELISA assay.
Participants receive tailored intensive care including brief advice on how to quit smoking, NRT, and intensive print materials to promote smoking cessation as in Arm I. Participants also receive individualized text based messages to promote smoking cessation for 6 months.